Hemab Therapeutics/X
Sep 2, 2025, 12:50
New COO at Hemab Therapeutics: Anant Murthy to Advance Rare Blood Disorder Treatments
Hemab Therapeutics posted on X:
”Hemab is growing fast, and we’re thrilled to announce our new Chief Operating Officer, Anant Murthy, PhD.
In this new role, Dr. Murthy will lead the company’s global efforts in market access, launch, and commercialization, bringing Hemab’s promising pipeline of treatments for Glanzmann thrombasthenia, Von Willebrand disease, and other neglected blood clotting disorders with high unmet needs to patients worldwide.
Read more here.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia